2315 Stock Overview
A biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2315 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.42 |
| 52 Week High | HK$12.80 |
| 52 Week Low | HK$5.60 |
| Beta | 0.77 |
| 1 Month Change | 40.33% |
| 3 Month Change | 33.65% |
| 1 Year Change | -27.29% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.62% |
Recent News & Updates
Health Check: How Prudently Does Biocytogen Pharmaceuticals (Beijing) (HKG:2315) Use Debt?
Dec 12
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?
May 08Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking
Apr 03Shareholder Returns
| 2315 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 6.2% | -3.9% | -0.5% |
| 1Y | -27.3% | -5.7% | 19.9% |
Return vs Industry: 2315 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 2315 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 2315 volatility | |
|---|---|
| 2315 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2315 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2315's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,040 | Yuelei Shen | biocytogen.com.cn |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary
| 2315 fundamental statistics | |
|---|---|
| Market cap | HK$3.36b |
| Earnings (TTM) | -HK$259.84m |
| Revenue (TTM) | HK$853.19m |
3.9x
P/S Ratio-12.9x
P/E RatioIs 2315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2315 income statement (TTM) | |
|---|---|
| Revenue | CN¥800.58m |
| Cost of Revenue | CN¥213.99m |
| Gross Profit | CN¥586.58m |
| Other Expenses | CN¥830.40m |
| Earnings | -CN¥243.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 73.27% |
| Net Profit Margin | -30.46% |
| Debt/Equity Ratio | 53.1% |
How did 2315 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CMB International Securities Limited |
| Ziyi Chen | Goldman Sachs |
| Kehan Meng | Haitong International Research Limited |